These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 2040185)

  • 1. Treatment of patients with anemia of malignancy with recombinant human erythropoietin.
    Herrmann F; Oster W; Mertelsmann R
    Contrib Nephrol; 1991; 88():238-45; discussion 246-7. PubMed ID: 2040185
    [No Abstract]   [Full Text] [Related]  

  • 2. Correction of anaemia with recombinant human erythropoietin.
    Ponticelli C; Casati S
    Nephron; 1989; 52(3):201-8. PubMed ID: 2662045
    [No Abstract]   [Full Text] [Related]  

  • 3. A randomized, placebo-controlled clinical trial of recombinant human erythropoietin in the anemia of prematurity.
    Mentzer WC; Shannon KM; Abels RI; Freeman P; Newton N; Thompson D; Phibbs RH
    Contrib Nephrol; 1991; 88():306-12; discussion 313. PubMed ID: 2040193
    [No Abstract]   [Full Text] [Related]  

  • 4. Guidelines for the use of recombinant human erythropoietin.
    Barosi G; Cazzola M; De Vincentiis A; Grossi A; Tura S
    Haematologica; 1994; 79(6):526-33. PubMed ID: 7896210
    [No Abstract]   [Full Text] [Related]  

  • 5. Erythropoietin.
    Haberl M
    Aust Nurses J; 1990 Sep; 20(2):29. PubMed ID: 2268202
    [No Abstract]   [Full Text] [Related]  

  • 6. [Recombinant human erythropoietin and chronic kidney failure: current situation and therapeutic implications].
    Romero González R; Torquet Escuder P
    Med Clin (Barc); 1990 Nov; 95(17):656-9. PubMed ID: 2089205
    [No Abstract]   [Full Text] [Related]  

  • 7. Improvement in anemia by recombinant human erythropoietin in patients with myelodysplastic syndrome and aplastic anemia.
    Hirashima K; Bessho M; Jinnai I
    Contrib Nephrol; 1991; 88():254-65. PubMed ID: 2040187
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of recombinant human erythropoietin in the management of anemia associated with acquired immunodeficiency syndrome.
    Garnick MB; Abels R; Rudnick SA
    Contrib Nephrol; 1991; 88():282-92; discussion 293-4. PubMed ID: 2040191
    [No Abstract]   [Full Text] [Related]  

  • 9. Erythropoietin for anemia.
    Med Lett Drugs Ther; 1989 Sep; 31(801):85-6. PubMed ID: 2671624
    [No Abstract]   [Full Text] [Related]  

  • 10. Recombinant human erythropoietin in children with cancer.
    MacMillan ML; Freedman MH
    J Pediatr Hematol Oncol; 1998; 20(3):187-9. PubMed ID: 9628427
    [No Abstract]   [Full Text] [Related]  

  • 11. Anaphylactic reaction to recombinant human erythropoietin.
    García JE; Senent C; Pascual C; Fernandez G; Perez-Carral C; Diaz-Tejeiro R; Gomez E; Sierra T
    Nephron; 1993; 65(4):636-7. PubMed ID: 8302424
    [No Abstract]   [Full Text] [Related]  

  • 12. [Erythropoietin in the prevention and treatment of anemias (a review of the literature)].
    Shevchenko IuL; Danil'chenko VV; Zhiburt EB; Serebrianaia NB; Khubulava GG; Belevitin AB
    Voen Med Zh; 1996 Nov; 317(11):45-8. PubMed ID: 9036631
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical application of recombinant erythropoietin in anemic cancer patients.
    Henry DH
    Hematol Oncol Clin North Am; 1994 Oct; 8(5):961-73. PubMed ID: 7852218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficiency of recombinant human erythropoietin treatment in anemic pregnant women with a kidney transplant.
    Szurkowski M; Wiecek A; Kokot F; Daniel K
    Nephron; 1994; 67(2):242-3. PubMed ID: 8072619
    [No Abstract]   [Full Text] [Related]  

  • 15. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.
    Robles NR
    Clin Drug Investig; 2016 Jun; 36(6):421-31. PubMed ID: 26894799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin.
    Beresford CH
    N Z Med J; 1989 Apr; 102(866):185-6. PubMed ID: 2652007
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of rHuEPO in treatment of uremic anemia prior to end-stage renal disease.
    Koene RA; Frenken LA
    Kidney Int Suppl; 1992 Oct; 38():S142-7. PubMed ID: 1405365
    [No Abstract]   [Full Text] [Related]  

  • 18. Strategies to optimize the use of erythropoietin and iron therapy in oncology patients.
    Ford PA; Mastoris J
    Transfusion; 2004 Dec; 44(12 Suppl):15S-25S. PubMed ID: 15585001
    [No Abstract]   [Full Text] [Related]  

  • 19. Economics of epoetin therapy.
    Grimm AM; Flaharty KK; Hopkins LE; Mauskopf J; Besarab A; Vlasses PH
    Clin Pharm; 1989 Nov; 8(11):807-10. PubMed ID: 2509130
    [No Abstract]   [Full Text] [Related]  

  • 20. Application of recombinant human erythropoietin in oncology.
    Spivak JL
    Cancer Invest; 1990; 8(2):301-2. PubMed ID: 2400953
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.